What is ERASCA's long-term outlook?
The long-term outlook for Erasca, Inc. (ERAS) is characterized by high volatility and heavy dependence on the success of its clinical pipeline. For the period between 2026 and 2030, market forecasts have anticipated that the stock will trade within a specific channel, with expectations often hovering between the $15 and $20 range for the 2026 fiscal year. The company’s trajectory is intrinsically tied to its ability to overcome the ongoing legal challenges related to patent and trade secret disputes, as well as its capacity to successfully navigate the regulatory hurdles required to bring its oncology programs to commercial viability. Investors view the long-term outlook as highly speculative, dependent on clinical breakthroughs, and potential shifts in the competitive landscape of the cancer drug industry, where success requires sustained innovation and significant R&D investment.
Related FAQs
Erasca reported a net loss and a wider-than-expected loss per share of sixty cents for the first quarter, reflecting intensive capital investments and rising research and development expenditures as the clinical-stage oncology enterprise advanced its...
Erasca, Inc. officially completed its initial public offering and began trading its shares on the NASDAQ Global Select Market under the ticker symbol ERAS on July 16, 2021.
Erasca, Inc. was officially founded in 2018 by a team of experienced oncology drug developers and life science entrepreneurs with a singular mission to erase cancer.
The consensus among Wall Street analysts covering Erasca (ERAS) is currently a "Buy.
Erasca, Inc., a clinical-stage precision oncology company dedicated to discovering, developing, and commercializing therapies for patients with cancer, is based in San Diego, California.
Erasca, Inc. is a clinical-stage oncology company that trades on the Nasdaq stock market under the ticker symbol ERAS.
Yes, Regencell Bioscience Holdings Limited (RGC) completed a 38-for-one forward stock split in June 2025. The company announced this split on June 2, 2025, and established a record date of June 12, 2025.
Erasca, Inc. trades on the Nasdaq stock exchange under the ticker symbol ERAS at approximately $18.15 per share.
Erasca (ERAS) is currently classified by many financial analysts as a "Buy," reflecting professional optimism regarding its potential in the precision oncology market.
Jonathan Lim received an elite international legal education across prominent academic institutions. He completed his foundational legal training at the National University of Singapore Faculty of Law, where he earned his primary law degree.
Recent news concerning Erasca, Inc. has been dominated by legal developments affecting investor sentiment.
Analysts tracking Erasca, Inc. maintain a favorable consensus rating, reflecting institutional optimism surrounding its precision oncology pipeline targeting difficult-to-treat RAS/MAPK pathway-driven cancers.
Erasca, Inc.
As of July 2026, Erasca, Inc. (ERAS) has a dividend yield of 0.00%. The company is a clinical-stage oncology firm that focuses on developing advanced treatments for cancer, and as such, it does not currently pay dividends to its shareholders.
Operating as a specialized precision oncology enterprise, Erasca researches and develops innovative therapeutic drug candidates targeted specifically at oncogenic drivers within the mitogen-activated protein kinase signaling pathway.